Objective: Despite on-going research into the underlying pathology of hypertensive disorders in pregnancy, maternal mortality is hardly decreasing. Current antihypertensive therapy is aimed at controlling symptoms and preventing severe courses of pregnancy. Traditional management focuses on blood pressure (BP) control, but does not consider individual hemodynamic variations. Hemodynamically guided therapy offers a personalized approach that can improve BP control and outcomes by treating the underlying pathophysiology. The aim of this review is to provide an overview of hemodynamically guided antihypertensive therapy in hypertensive disorders of pregnancy and to present the results of recent intervention trials in this area. Methods: Literature searches were conducted in the electronic databases PubMed, CENTRAL, and Google scholar from inception to May 2024 for studies that used maternal hemodynamic parameters like cardiac output (CO) or TPVR (total peripheral vascular resistance) to guide antihypertensive therapy in pregnant women with hypertensive disorders or at elevated risk for developing preeclampsia. The review included intervention studies. Results: A total of five studies met the inclusion criteria. All studies showed improved BP control when the antihypertensive medication administered was matched to hemodynamic characteristics of the women being treated. Using a personalized approach, pregnancy complications were significantly reduced in patients with both hypo- or hyperdynamic circulation, even in patients with a history of preeclampsia. Conclusion: The study shows that hemodynamically triggered antihypertensive therapy can improve outcomes for both mother and child in cases of hypertensive pregnancy disorders. However, further placebo-controlled studies are necessary before a final assessment of this therapy can be made.
To present a case of a patient with recurrent spontaneous ovarian hyperstimulation syndrome (sOHSS) and a previously undescribed mutation of the follicle-stimulating hormone receptor (FSHR). Case report. A 23-year-old pregnant woman (gravida II) with recurrent spontaneous ovarian hyperstimulation during 2 consecutive singleton pregnancies. Spontaneous conception in the presence of a heterozygous FSHR gene mutation Clinical course of sOHSS, hormonal profile, sonographic findings, molecular genetic results, and maternal and fetal outcomes. The patient presented at 12 weeks’ gestation with massively enlarged bilateral multicystic ovaries (‟kissing ovaries”) and mild ascites, without pleural effusion. Molecular genetic analysis revealed a previously unreported heterozygous FSHR mutation (c.1379T>A, p.Leu460Gln) in the transmembrane domain, classified as likely pathogenic according to American College of Medical Genetics and Genomics criteria. Conservative management resulted in gradual regression of ovarian size from the second trimester onward. The pregnancy was complicated by fetal growth restriction with normal uteroplacental and fetal perfusion parameters. Delivery by elective cesarean section at 38+0 weeks resulted in a healthy neonate. The discovery of a novel FSHR gene mutation, which is likely associated with sOHSS in this case, suggests that genetic factors may influence the development of this rare condition. It underlines the importance of considering genetic testing in managing and diagnosing sOHSS, potentially guiding more personalized and effective treatment strategies for affected women.
Background/Objectives: This cohort study aims to evaluate the association between antenatal blood pressure levels and postpartum cardiovascular outcomes in women with preeclampsia and/or fetal growth restriction (FGR). The objective of the study was to test the hypothesis that blood pressure levels during pregnancy are associated with cardiovascular health after delivery. Methods: The study was conducted at a tertiary hospital in Germany and involved women who developed preeclampsia and/or FGR during their pregnancies between 2021 and 2024. Participants were invited for cardiovascular follow-up consultations at 6 weeks and 6 months postpartum. VICORDER measurements were used for cardiovascular function assessment. Results were compared between the group with persisting hypertension and normotensive women at each study visit to assess the long-term progression of hypertensive disorders in relation to antenatal blood pressure levels. Statistical analysis employed Mann–Whitney U tests and adjusted odds ratios (aORs). Results: Of the 103 women who attended postpartum cardiovascular consultations during the study period, a substantial proportion still had elevated blood pressure at 6 weeks (51.49%) and 6 months (42.86%) after delivery. Women with persistent hypertension had higher systolic and diastolic blood pressure throughout pregnancy (p < 0.001), used antihypertensive medication more frequently (p < 0.001) and showed significantly increased arterial stiffness up to 6 weeks postpartum compared with normotensive women (7.4 m/s vs. 6.7 m/s, p < 0.001). In adjusted analyses, higher blood pressure levels during pregnancy were significant predictors of persistent postpartum hypertension (p < 0.05). Except for systolic blood pressure in the 3rd trimester at the 6-week follow-up, every 10 mmHg increase in blood pressure during pregnancy was associated with higher odds of postpartum hypertension, with aORs ranging from 1.82 to 3.42 at 6 weeks and from 2.18 to 5.51 at 6 months postpartum (depending on the trimester). Conclusions: Maintaining healthy blood pressure levels during pregnancy may reduce the long-term cardiovascular risk for mothers. These findings underscore the importance of early detection and consistent management of hypertension in expectant mothers with hypertensive pregnancy disorders. Further research is required to identify optimal blood pressure management strategies during pregnancy that could improve immediate and long-term maternal health outcomes.